ZLAB Zai Lab
- 16.570
- -0.110-0.66%
- 17.010
- +0.440+2.66%
Zai Lab News
Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) opened up nearly 5%, net product revenue of US$87.1 million in the first quarter increased 39% year-on-year
Zaiding Pharmaceutical (09688) opened nearly 5% higher in early trading. As of press release, it rose 4.86% to HK$13.8, with a turnover of HK$1,357,900.
Zai Lab Q1 Loss Widens Despite Higher Revenue
Zai Lab (HKG:9688) posted a net loss of $53.5 million for the first quarter, compared with a loss of $49.1 million in the year-ago quarter, according to a Thursday filing on the Hong Kong bourse. The
Zaiding Pharmaceutical's net product revenue of US$87.1 million in the first quarter increased 39% year-on-year
Zaiding Pharmaceutical (09688) announced that total net product revenue for the first quarter of 2024 was US$87.1 million, up 39% year on year; 43% year on year based on fixed exchange rate (CER); R&D expenses were US$54.6 million, up 12.58% year on year; and cash reserves as of March 31, 2024 were US$750.8 million. According to the announcement, the increase in product revenue was mainly due to an increase in sales volume, including Wei Weijia's launch in September last year, and a reduction in sales rebates given to dealers due to price cuts for some products due to inclusion in China's National Medical Insurance Drug Catalogue (NRDL).
Zaiding Pharmaceutical (09688)'s net product revenue of US$87.1 million in the first quarter increased 39% year-on-year
Zaiding Pharmaceutical (09688) announced that the total net product revenue for the first quarter of 2024 was US$87.1 million...
Zaiding Pharmaceutical (09688.HK): Product revenue of US$87.1 million in the first quarter increased 39% year-on-year
Gelonghui, May 9 | Zaiding Pharmaceutical (09688.HK) announced financial results for the first quarter of 2024. Product revenue for the first quarter of 2024 was US$87.1 million and US$62.8 million for the same period of 2023, an increase of 39% year-on-year, and 43% year-on-year increase according to CER. The increase in product revenue is mainly due to an increase in sales volume, including Wei Weijia's launch in September last year, and a reduction in sales rebates given to dealers due to price cuts for some products due to inclusion in China's National Medical Insurance Drug List (NRDL). R&D expenses for the first quarter of 2024 were $54.6 million, 202
ZAI LAB: UNAUDITED RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND CORPORATE UPDATES
Zai Lab 1Q Loss/Shr 5c >ZLAB
Zai Lab 1Q Loss/Shr 5c >ZLAB
Zai Lab 1Q Rev $87.1M >ZLAB
Zai Lab 1Q Rev $87.1M >ZLAB
10-Q: Quarterly report
Zai Lab Q1 2024 GAAP EPS $(0.55) Beats $(0.94) Estimate, Sales $87.10M Beat $75.24M Estimate
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.94) by 41.49 percent. The company reported quarterly sales of $87.10 million whic
Press Release: Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates -- Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth; 43%
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Monday Trading
Asian equities traded in the US as American depositary receipts opened the week slightly higher in Monday morning trading, led by tech stocks, rising 0.16% to 1,918.19 on the S&P Asia 50 ADR Index. Fr
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher
Asian equities traded in the US as American depositary receipts were trending sharply higher Friday morning, rising 1.06% to 1,903.74 on the S&P Asia 50 ADR Index. With the gain, the index is set to e
再鼎醫藥：2023 年度報告
Zai Lab Limited's (NASDAQ:ZLAB) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 5.9x Zai Lab Limited (NASDAQ:ZLAB) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United State
Zaiding Pharmaceutical (09688.HK) plans to hold a board meeting on May 9 (Hong Kong time) to approve the first quarter results
Gelonghui, April 26, 丨 Zaiding Pharmaceutical (09688.HK) announced that the Board Review Committee will review and approve (including) the unaudited quarterly results (“First Quarter Results”) of the Company and its subsidiaries for the 3 months ended March 31, 2024, prepared in accordance with US GAAP and applicable rules of the US Securities and Exchange Commission (“First Quarter Results”). If the first quarter results are approved by the Audit Committee, the company will do so on Wednesday, May 8, 2024 (US)
再鼎醫藥：審核委員會行動通告及2024年第一季度業績公告的發佈日期
Zai Lab Files Automatic Ordinary Shares Offering
Express News | Zai Lab Ltd : JP Morgan Cuts Target Price to $38 From $44
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading
After opening the trading session in positive territory, Asian equities traded in the US as American depositary receipts fell flat Wednesday morning, declining 0.061% to 1,823.73 on the S&P Asia 50 AD
Analysis
Price Target
No Data
